TWi Pharmaceuticals, Inc. today announced that it launched its generic version of Par Pharmaceutical's MEGACE ES® (megestrol acetate oral suspension) 625mg/5ml after the United States District Court ...

NEWARK (CN) - Par Pharmaceuticals pleaded guilty and will pay $45 million in criminal and civil fines for promoting its anorexia drug Megace ES for off-label uses, federal prosecutors said. Doctors ...

NEWARK, N.J. (AP) — A New Jersey-based drugmaker agreed on Tuesday to pay $45 million to resolve charges that it improperly marketed its weight-gain drug to frail seniors particularly vulnerable to ...

TAIPEI, Taiwan, Dec. 15, 2015 /PRNewswire/ -- TWi Pharmaceuticals, Inc. ("TWi") (Stock Ticker: 4180.TT) today announced that it has received a favorable decision from the U.S. Court of Appeals for the ...

March 5 (Reuters) - Par Pharmaceutical Cos, a generic drugmaker, has pleaded guilty to improperly marketing a medication intended to address appetite loss in AIDS patients, and agreed to pay $45 ...

Megestrol acetate 125mg/mL; oral susp; lemon-lime flavor. Do not substitute with other megestrol suspensions (not interchangeable). History of thromboembolic disease. Monitor for signs/symptoms of ...

A New Jersey-based drugmaker agreed on Tuesday to pay $45 million to resolve charges that it improperly marketed its weight-gain drug to frail seniors particularly vulnerable to its side effects, ...

LONDON (MarketWatch) -- Par Pharmaceutical Companies said it's won Food and Drug Administration approval for Megace ES, a treatment for anorexia, cachexia or AIDS-related weight loss. Par said Megace ...